Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non–Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial

PURPOSE: Patients with centrally located early-stage non–small-cell lung cancer (NSCLC) are at a higher risk of toxicity from high-dose ablative radiotherapy. NRG Oncology/RTOG 0813 was a phase I/II study designed to determine the maximum tolerated dose (MTD), efficacy, and toxicity of stereotactic...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Clin Oncol
Auteurs principaux: Bezjak, Andrea, Paulus, Rebecca, Gaspar, Laurie E., Timmerman, Robert D., Straube, William L., Ryan, William F., Garces, Yolanda I., Pu, Anthony T., Singh, Anurag K., Videtic, Gregory M., McGarry, Ronald C., Iyengar, Puneeth, Pantarotto, Jason R., Urbanic, James J., Sun, Alexander Y., Daly, Megan E., Grills, Inga S., Sperduto, Paul, Normolle, Daniel P., Bradley, Jeffrey D., Choy, Hak
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2019
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6524984/
https://ncbi.nlm.nih.gov/pubmed/30943123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.18.00622
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires